8-KLeadership ChangesRegulation FDExhibits & Filings

CARDINAL HEALTH INC 8-K Report, Executive Changes (Apr 10, 2012)

Filed April 10, 2012For Securities:CAH

Summary

Cardinal Health, Inc. (CAH) filed an 8-K report on April 10, 2012, primarily announcing a significant leadership change within its Medical segment. Michael A. Lynch will be stepping down as CEO of the Medical segment, with his departure effective April 16, 2012. The company has entered into a separation agreement with Mr. Lynch, outlining terms for his continued employment in a non-officer role until a chosen date between June 30 and September 22, 2012, after which he will receive a comprehensive severance package. Simultaneously, Cardinal Health announced the appointment of Donald M. Casey, Jr. as the new CEO of the Medical segment, also effective April 16, 2012. This transition signals a strategic shift in leadership for a key business division, and investors will be keen to understand the implications for the segment's future performance and strategy under new leadership. The filing also details the terms of Mr. Lynch's separation, including continued benefits, equity vesting, and post-employment restrictions.

Key Highlights

  • 1Michael A. Lynch is stepping down as CEO of Cardinal Health's Medical segment, effective April 16, 2012.
  • 2Donald M. Casey, Jr. has been appointed as the new CEO of the Medical segment, succeeding Mr. Lynch.
  • 3Mr. Lynch will remain with the company in a non-officer role until at least June 30, 2012, with his departure date selectable up to September 22, 2012.
  • 4A separation agreement with Mr. Lynch includes severance pay equivalent to two years of his base salary plus target bonus.
  • 5Mr. Lynch will receive his full-year fiscal 2012 bonus based on Medical segment results.
  • 6The separation agreement provides for continued benefits, including 18 months of subsidized health coverage and outplacement services.
  • 7Mr. Lynch's equity awards will continue to vest through his termination date, and he remains bound by confidentiality and non-compete/non-solicitation clauses for a defined period post-employment.

Frequently Asked Questions

The filing states that Michael A. Lynch will cease to be the chief executive officer of the Medical segment. While the specific reasons for his departure are not detailed, the company has entered into a separation agreement with him, indicating an amicable separation process.

Mr. Lynch will receive severance payable over two years, equal to two years of his current annual base salary plus target annual bonus. He will also receive his full-year fiscal 2012 annual bonus based on Medical segment results. Additionally, he will receive 18 months of subsidized health and medical benefit plan coverage and outplacement services for up to two years. His unvested equity awards will continue to vest.

Donald M. Casey, Jr. has been appointed as the new chief executive officer of the Medical segment, effective April 16, 2012.

Yes, Mr. Lynch remains subject to a Confidentiality and Business Protection Agreement. This includes two-year non-competition and non-solicitation restrictions, with the restricted period ending two years after he transitions to his non-officer role. The non-competition restrictions are narrowed during the final year of this period.